Canada Poultry Medicine Market

Canada Poultry Medicine Market Size Insights Forecasts to 2035

• The Canada Poultry Medicine Market Size was estimated at USD 3.25 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 6.29% from 2025 to 2035
• The Canada Poultry Medicine Market Size is Expected to Reach USD 6.36 Billion by 2035

According to a Research Report Published by Decisions Advisors and Consulting, The Canada Poultry Medicine Market Size is anticipated to Reach USD 6.36 Billion by 2035, Growing at a CAGR of 6.29% from 2025 to 2035. The growing poultry consumption is the main factor propelling the poultry pharmaceutical market's expansion as consumers turn more and more to reasonably priced, high-protein foods like chicken and eggs. Besides, the market is expanding due to the increase in commercial poultry farming, the rising demand for poultry products, and the increasing prevalence of poultry diseases.

Market Overview

The Canadian poultry medicine market refers to the industry focused on the production, distribution, and use of pharmaceuticals intended to preserve the health and productivity of poultry animals. Further, the species raised for meat, eggs, or breeding is the key focus of new market opportunities. Vaccines, antibiotics, antiparasitics, probiotics, immune-stimulants, and feed additives are among the many products available in this market that are used to prevent, treat, and manage infectious, metabolic, and parasitic diseases that affect chickens. In poultry farming, the sector is vital to disease prevention and biosecurity, guaranteeing food safety, improving flock health, lowering mortality, and maintaining production levels. Further, growing poultry consumption, the growth of poultry farming, and investments in the infrastructure of veterinary healthcare are the main drivers of demand.

Canada produced $6.8 billion worth of poultry and egg products in 2024, which accounted for 7.0% of farming operations' cash receipts. In Canada, there were 1,270 egg producers, 237 broiler hatching egg producers, 504 registered turkey producers, and 2,884 regulated chicken producers in 2024. Furthermore, Quebec and Ontario produced 61% of Canada's 1.4 billion kilograms of chicken in 2024.

Report Coverage

This research report categorises the market for the Canada poultry medicine market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Canada poultry medicine market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Canada poultry medicine market.

Driving Factors

The market for Canadian poultry medicine is driven by the poultry industry makes investments in cutting-edge treatments, vaccines, and dietary supplements to protect flock health. Canada's growing poultry consumption is driving up demand for disease management strategies and building a robust market for both preventive and curative medications. In Canada, veterinary pharmaceutical companies are concentrating on developing broad-spectrum vaccines and antibiotics specifically designed to treat avian diseases. Further, regulations that promote the safe and efficient use of medications are being shaped by government initiatives supporting the management of poultry health. In Canada, the detection and treatment of poultry diseases is being streamlined by biotech-driven innovation in targeted therapies and diagnostics. Further, key pharmaceutical companies, research institutes, and poultry associations are working together strategically to promote innovation and uptake in medicine.

The Canadian Poultry Research Council (CPRC), Agriculture and Agri-Food Canada (AAFC) have awarded six University of Guelph researchers more than a million dollars to investigate innovative methods for enhancing food safety and poultry health. The Sustainable Canadian Agricultural Partnership (Sustainable CAP), a five-year federal-provincial-territorial initiative to improve the competitiveness, innovation, and resilience of Canada's agriculture, agri-food, and agri-based products sector, includes more than $5.1 million in funding for the CPRC through the AgriScience Program Clusters Component.

Restraining Factors

Despite the substantial market expansion, some factors slow down the growth rate, such as high R&D costs, strict regulatory frameworks, and concerns about antimicrobial resistance. Despite the growing demand for poultry health solutions, these factors slow the rate of product approvals and adoption.

Market Segmentation

The Canada poultry medicine market share is classified into product, disease, and route of administration.

• The biologics segment held a significant share in 2024 and is expected to grow at a rapid pace over the forecast period.

The Canada poultry medicine market is divided by product into biologics and pharmaceuticals. Among these, the biologics segment held a significant share in 2024 and is expected to grow at a rapid pace over the forecast period. Their efficiency and compliance with sustainable farming practices are the main drivers of this expansion via Immunostimulants, probiotics, live attenuated, recombinant, and mRNA vaccines. The use of biologics has accelerated due to regulations on antibiotic use and growing concerns about antimicrobial resistance. Furthermore, novel next-generation mRNA-based vaccines and recombinant vector vaccines provide enhanced safety, specificity, and deployment simplicity.

• The Newcastle disease segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

The Canada poultry medicine market is segmented by disease into Newcastle disease, infectious bronchitis, infectious bursal disease, coccidiosis, salmonella, Marek's disease, and others. Among these, the Newcastle disease segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. This is due to high contagiousness and significant economic effects; virulent strains such as Newcastle disease (ND) represent a serious threat to the poultry industry. Poultry outbreaks can result in serious respiratory and neurological illnesses, with mortality rates a reduced productivity. Further, its affordability and capacity to produce strong immunity, vaccination, especially with live attenuated vaccines, remain the main preventive strategy.

• The injectable segment held a significant share in 2024 and is anticipated to grow at a rapid pace during the forecast period.

The Canada poultry medicine market is differentiated by route of administration into oral, injectable, topical, and others. Among these, the injectable segment held a significant share in 2024 and is anticipated to grow at a rapid pace during the forecast period. This segment is growing due to serious illnesses like avian influenza, infectious bursal disease, and Newcastle disease, which require precise dosing and strong immune activation. Moreover, recent advancements like needle-free delivery and sophisticated adjuvants have improved safety, effectiveness, and administration ease, solidifying injectables' dominant position in poultry health management and vaccine distribution.

Competitive Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the Canada poultry medicine market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Phibro Animal Health Corporation
• Bimeda Canada
• Ceva Canada
• Dechra Veterinary Products, Inc.
• Poultry Health Services

• Others

Recent Developments:

• In December 2024, Novibio launched a product to enhance intestinal health in poultry. The Canadian company introduced the Poultrirom Plus, a new feed additive that was designed specifically for broilers and turkeys. The company noted that this cutting-edge product demonstrates its dedication to using natural solutions to improve poultry productivity and health.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Canada, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the Canada poultry medicine market based on the below-mentioned segments:

Canada Poultry Medicine Market, By Product

• Biologics
• Pharmaceuticals

Canada Poultry Medicine Market, By Disease

• Newcastle Disease
• Infectious Bronchitis
• Infectious Bursal Disease
• Coccidiosis
• Salmonella
• Marek's Disease
• Others

Canada Poultry Medicine Market, By Route of Administration

• Oral
• Injectable
• Topical
• Others

FAQ

Q: What is the market size and growth forecast for Canada's poultry medicine?
A: The market was estimated at USD 3.25 billion in 2024 and is expected to grow at a CAGR of 6.29% to reach USD 6.36 billion by 2035.

Q: What products are included in the Canadian poultry medicine market?
A: The market includes biologics (immunostimulants, probiotics, live attenuated, recombinant, and mRNA vaccines) and pharmaceuticals.

Q: Which diseases are primarily targeted in this market?
A: Key diseases include Newcastle disease (which dominated the market in 2024), infectious bronchitis, infectious bursal disease, coccidiosis, salmonella, Marek's disease, and others.

Q: What are the main routes of administration?
A: Oral, injectable (which held a significant share in 2024), topical, and others.

Q: What drives the growth of this market?
A: Rising poultry consumption, expansion of commercial poultry farming, increased prevalence of poultry diseases, government support, research investments, and innovation in vaccines and medicines.

Q: What restrains market growth?
A: High R&D costs, stringent regulations, and antimicrobial resistance concerns.

Q: Who are the key players?
A: Phibro Animal Health Corporation, Bimeda Canada, Ceva Canada, Dechra Veterinary Products, Inc., Poultry Health Services, among others.

Q: Any notable recent developments?
A: Novibio launched "Poultrirom Plus," a feed additive for broilers and turkeys to enhance intestinal health, in December 2024.